BioGaia Valuation Multiples

BioGaia Overview

About BioGaia

BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee’s dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions; Asia Pacific, Europe, the Middle East, Africa, and the Americas.

Founded

1990

HQ

Employees

225

Website

biogaia.se

Sectors

Nutraceuticals & CosmeceuticalsBioTech

Financials (LTM)

Revenue: $174M

EBITDA: $51M

EV

$1B

Valuation Multiples

Multiples.vc

Start free trial

BioGaia Financials

BioGaia reported last 12-month revenue of $174M and EBITDA of $51M.

In the same LTM period, BioGaia generated $128M in gross profit, $51M in EBITDA, and $39M in net income.

BioGaia P&L

In the most recent fiscal year, BioGaia reported revenue of $173M and EBITDA of $49M.

BioGaia expects next 12-month revenue of XXX and NTM EBITDA of XXX

BioGaia Stock Performance

BioGaia has current market cap of $1B, and enterprise value of $1B.

BioGaia's stock price is $12.73.

BioGaia Valuation Multiples

BioGaia trades at 6.9x EV/Revenue multiple, and 23.4x EV/EBITDA.

BioGaia Financial Valuation Multiples

As of April 11, 2026, BioGaia has market cap of $1B and EV of $1B.

Equity research analysts estimate BioGaia's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

BioGaia has a P/E ratio of 32.9x.

BioGaia Margins & Growth Rates

BioGaia's revenue in the last 12 month grew by 5%.

BioGaia's revenue per employee in the last FY averaged $0.8M, while opex per employee averaged $0.3M for the same period.

BioGaia's rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

BioGaia's rule of X is 50% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

BioGaia Public Comps

See public comps and valuation multiples for other Nutraceuticals & Cosmeceuticals comps.

BioGaia M&A Activity

BioGaia acquired XXX companies to date.

Last acquisition by BioGaia was on XXXXXXXX, XXXXX. BioGaia acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

BioGaia Investment Activity

BioGaia invested in XXX companies to date.

BioGaia made its latest investment on XXXXXXXX, XXXXX. BioGaia invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).